Skip to main navigation menu Skip to main content Skip to site footer

No. 3 (2025)

ORIRGINAL RESEARCH

Metabolic Consequences of Antipsychotic Therapy: Psychiatrists’ Opinion

https://doi.org/10.48612/psyph/6rr5-31p2-nbp2

Published 2025-09-30

  • E.G. Kornetova
    • ,
  • S.A. Galkin
    • ,
  • I.A. Mednova
    • ,
  • T.V. Kazennykh
    • ,
  • T.Yu. Gracheva
    • ,
  • V.A. Sorokina
    • ,
  • A.N. Kornetov

E.G. Kornetova
Tomsk National Research Medical Center, Russian Academy of Sciences

S.A. Galkin
Tomsk National Research Medical Center, Russian Academy of Sciences

I.A. Mednova
Tomsk National Research Medical Center, Russian Academy of Sciences

T.V. Kazennykh
Tomsk National Research Medical Center, Russian Academy of Sciences

T.Yu. Gracheva
Tomsk National Research Medical Center, Russian Academy of Sciences

V.A. Sorokina
Kuzbass Clinical Psychiatric Hospital

A.N. Kornetov
Tomsk National Research Medical Center, Russian Academy of Sciences

Abstract

Relevance. The American Psychiatric Association (APA), in collaboration with other medical societies, developed recommendations for the monitoring of metabolic syndrome in patients taking antipsychotics back in 2004. Despite these simple recommendations and recognition by psychiatrists of the importance of monitoring metabolic disorders, a number of studies indicate non-compliance with these recommendations by physicians prescribing antipsychotics.

The aim — to study the level of awareness, attitudes and compliance of psychiatrists with the basic recommendations for monitoring metabolic disorders in patients taking antipsychotics, as well as the perceived barriers to its implementation.

Material and methods. An anonymous survey of 70 psychiatrists in Kemerovo and Tomsk was conducted using the questionnaire “Primary Care Providers’ Views on Metabolic Monitoring of Outpatients Taking Antipsychotic Medication”, developed for primary care physicians in order to assess their attitudes toward barriers to monitoring metabolic disorders in patients and characterize their beliefs about responsibility for conducting such monitoring.

Results. The majority (97.1%) of physicians were well aware of the metabolic risks associated with antipsychotic drugs. At the same time, 70% of physicians agreed with the statement that individuals with schizophrenia are at higher risk of developing metabolic disorders than the rest of the population. Although many (40.1%) believe that monitoring risk factors for metabolic disorders is the responsibility of primary care physicians, most psychiatrists surveyed still agreed that this task is part of their responsibilities. About half (51.4%) of respondents disagreed with the statement that it is the responsibility of a psychiatrist to prescribe medications to treat elements of metabolic dysfunction. Among all possible obstacles, the greatest impact on monitoring, according to psychiatrists, is the lack of medications in their arsenal for the correction of metabolic disorders — 18.6%.

Conclusion. A survey of psychiatrists regarding the monitoring of metabolic disorders in patients taking antipsychotics indicates a high degree of awareness of the side effects of antipsychotic therapy and a willingness to cooperate in screening. However, the main obstacle on this path, according to psychiatrists, is the lack of drugs in their arsenal to correct metabolic disorders.

Keywords

survey, opinion of psychiatrists, schizophrenia, metabolic syndrome, metabolic disorders, monitoring

PDF (Русский)

References

  1. Allison S., Bastiampillai T., Looi J.C. et al. The new World Mental Health Report: Believing impossible things // Australas Psychiatry. – 2023. – Vol. 31. – Pp. 182–185. – https://doi.org/10.1177/10398562231154806
  2. Wu Y., Wang L., Tao M. et al. Changing trends in the global burden of mental disorders from 1990 to 2019 and predicted levels in 25 years // Epidemiol Psychiatr Sci. – 2023. – Vol. 32. – e63. – https://doi.org/10.1017/S2045796023000756
  3. Медведев В.Э. Применение антипсихотиков в реальной клинической практике в России (по результатам программы EPIDEMICUS) // Неврология, нейропсихиатрия, психосоматика. – 2025. – № 1. – С. 24–33. – https://doi.org/10.14412/2074-2711-2025-1-24-33
  4. Leucht S., Priller J., Davis J.M. Antipsychotic drugs: A concise review of history, classification, indications, mechanism, efficacy, side effects, dosing, and clinical application // Am J Psychiatry. – 2024. – Vol. 181. – Pp. 865–878. – https://doi.org/10.1176/appi.ajp.20240738
  5. Garakani A., Freire R.C., Buono F.D. et al. An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol // PLoS One. – 2022. – Vol. 17. – e0269772. – https://doi.org/10.1371/journal.pone.0269772
  6. Корнетова Е.Г., Герасимова В.И., Гончарова А.А. и др. Метаболический синдром в госпитальной популяции больных шизофренией в регионе Западной Сибири // Психиатрия. – 2021. – № 4. – С. 52–60. – https://doi.org/10.30629/2618-6667-2021-19-4-52-60
  7. Петрова Н.Н., Семенова Н.В. Метаболический синдром и антипсихотическая терапия шизофрении // Журнал неврологии и психиатрии имени С.С. Корсакова. – 2024. – № 11. – С. 165–170. – https://doi.org/10.17116/jnevro2024124111165
  8. Abdel Aziz K., Mohd Ahmed H., Stip E. et al. Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders // Int Clin Psychopharmacol. – 2024. – Vol. 39. – Pp. 257–266. – https://doi.org/10.1097/YIC.0000000000000538
  9. Корнетова Е.Г., Галкин С.А., Корнетов А.Н. и др. Сравнительное исследование метаболических нарушений у стационарных пациентов с шизофренией и аффективными расстройствами // Социальная и клиническая психиатрия. – 2024. – № 2. – С. 5–12.
  10. Галкин С.А., Корнетова Е.Г., Меднова И.А. и др. Распространенность и факторы риска синдрома удлинения интервала QT у пациентов с шизофренией на фоне приема антипсихотиков // Современная терапия психических расстройств. – 2024. – № 2. – С. 32–39. – https://doi.org/10.21265/PSYPH.2024.31.31.004
  11. Peng P., Li J., Chen Y. et al. Associations between antipsychotics and the risk of incident cardiovascular diseases in individuals with schizophrenia: A nested case–control study // BMJ Ment Health. – 2023. – Vol. 26. – e300501. – https://doi.org/10.1136/bmjment-2022-300501
  12. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes // Diabetes Care. – 2004. – Vol. 27. – Pp. 596–601. – https://doi.org/10.2337/diacare.27.2.596
  13. Essock S.M., Covell N.H., Leckman–Westin E. et al. Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in New York State // Psychiatr Serv. – 2009. – Vol. 60. – Pp. 1595–602. – https://doi.org/10.1176/ps.2009.60.12.1595
  14. Morrato E.H., Druss B., Hartung D.M. et al. Metabolic testing rates in 3 state medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs // Arch Gen Psychiatry. – 2010. – Vol. 67. – Pp. 17–24. – https://doi.org/10.1001/archgenpsychiatry.2009.179
  15. Mangurian C., Giwa F., Shumway M. et al. Primary care providers’ views on metabolic monitoring of outpatients taking antipsychotic medication // Psychiatr Serv. – 2013. – Vol. 64. – Pp. 597–599. – https://doi.org/10.1176/appi.ps.002542012
  16. McLaren J.L., Brunette M.F., McHugo G.J. et al. Monitoring of patients on second-generation antipsychotics: a national survey of child psychiatrists // Psychiatr Serv. – 2017. – Vol. 68. – Art. 961. – https://doi.org/10.1176/appi.ps.201500553
  17. Клинические рекомендации. Шизофрения. Взрослые / Минздрав РФ. – Москва, 2024. – 217 с.
  18. Kornetova E.G., Kornetov A.N., Mednova I.A. et al. Changes in body fat and related biochemical parameters associated with atypical antipsychotic drug treatment in schizophrenia patients with or without metabolic syndrome // Front Psychiatry. – 2019. – Vol. 10. – Art. 803. – https://doi.org/10.3389/fpsyt.2019.00803
  19. Abdulhaq B., Dardas L.A., Sami O. Monitoring for the metabolic side effects of second–generation antipsychotic medications: Psychiatrists’ views and practices // Perspect Psychiatr Care. – 2021. – Vol. 57. – Pp. 1237–1243. – https://doi.org/10.1111/ppc.12679
  20. Ijaz S., Bolea B., Davies S. et al. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: A review of systematic reviews // BMC Psychiatry. – 2018. – Vol. 18. – Art. 275. – https://doi.org/10.1186/s12888-018-1848-y
  21. Горобец Л.Н., Буланов В.С., Литвинов А.В. Эффективность и переносимость коррекционной терапии частичным агонистом дофаминовых рецепторов арипипразолом нейролептической гиперпролактинемии у больных с расстройствами шизофренического спектра // Социальная и клиническая психиатрия. – 2023. – № 2. – С. 42–50.
  22. Siwek M., Wojtasik–Bakalarz K., Krupa A.J., Chrobak A.A. Brexpiprazole-pharmacologic properties and use in schizophrenia and mood disorders // Brain Sci. – 2023. – Vol. 13. – Art. 397. – https://doi.org/10.3390/brainsci13030397
  23. Медведев В.Э. Комплексная терапия шизофрении: проблемы и решения // Психиатрия и психофармакотерапия. – 2023. – № 5. – С. 29–42.
  24. Быков Ю.В., Беккер Р.А. Антипсихотик третьего поколения арипипразол: эффективность и безопасность при расстройствах шизофренического спектра (анализ современных данных) // Психиатрия и психофармакотерапия. – 2023. – № 2. – С. 17–34.
  25. Allison S., Bastiampillai T., Looi J.C. et al. The new World Mental Health Report: Believing impossible things // Australas Psychiatry. – 2023. – Vol. 31. – Pp. 182–185. – https://doi.org/10.1177/10398562231154806
  26. Wu Y., Wang L., Tao M. et al. Changing trends in the global burden of mental disorders from 1990 to 2019 and predicted levels in 25 years // Epidemiol Psychiatr Sci. – 2023. – Vol. 32. – e63. – https://doi.org/10.1017/S2045796023000756
  27. Медведев В.Э. Применение антипсихотиков в реальной клинической практике в России (по результатам программы EPIDEMICUS) // Неврология, нейропсихиатрия, психосоматика. – 2025. – № 1. – С. 24–33. – https://doi.org/10.14412/2074-2711-2025-1-24-33
  28. Leucht S., Priller J., Davis J.M. Antipsychotic drugs: A concise review of history, classification, indications, mechanism, efficacy, side effects, dosing, and clinical application // Am J Psychiatry. – 2024. – Vol. 181. – Pp. 865–878. – https://doi.org/10.1176/appi.ajp.20240738
  29. Garakani A., Freire R.C., Buono F.D. et al. An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol // PLoS One. – 2022. – Vol. 17. – e0269772. – https://doi.org/10.1371/journal.pone.0269772
  30. Корнетова Е.Г., Герасимова В.И., Гончарова А.А. и др. Метаболический синдром в госпитальной популяции больных шизофренией в регионе Западной Сибири // Психиатрия. – 2021. – № 4. – С. 52–60. – https://doi.org/10.30629/2618-6667-2021-19-4-52-60
  31. Петрова Н.Н., Семенова Н.В. Метаболический синдром и антипсихотическая терапия шизофрении // Журнал неврологии и психиатрии имени С.С. Корсакова. – 2024. – № 11. – С. 165–170. – https://doi.org/10.17116/jnevro2024124111165
  32. Abdel Aziz K., Mohd Ahmed H., Stip E. et al. Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders // Int Clin Psychopharmacol. – 2024. – Vol. 39. – Pp. 257–266. – https://doi.org/10.1097/YIC.0000000000000538
  33. Корнетова Е.Г., Галкин С.А., Корнетов А.Н. и др. Сравнительное исследование метаболических нарушений у стационарных пациентов с шизофренией и аффективными расстройствами // Социальная и клиническая психиатрия. – 2024. – № 2. – С. 5–12.
  34. Галкин С.А., Корнетова Е.Г., Меднова И.А. и др. Распространенность и факторы риска синдрома удлинения интервала QT у пациентов с шизофренией на фоне приема антипсихотиков // Современная терапия психических расстройств. – 2024. – № 2. – С. 32–39. – https://doi.org/10.21265/PSYPH.2024.31.31.004
  35. Peng P., Li J., Chen Y. et al. Associations between antipsychotics and the risk of incident cardiovascular diseases in individuals with schizophrenia: A nested case–control study // BMJ Ment Health. – 2023. – Vol. 26. – e300501. – https://doi.org/10.1136/bmjment-2022-300501
  36. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes // Diabetes Care. – 2004. – Vol. 27. – Pp. 596–601. – https://doi.org/10.2337/diacare.27.2.596
  37. Essock S.M., Covell N.H., Leckman–Westin E. et al. Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in New York State // Psychiatr Serv. – 2009. – Vol. 60. – Pp. 1595–602. – https://doi.org/10.1176/ps.2009.60.12.1595
  38. Morrato E.H., Druss B., Hartung D.M. et al. Metabolic testing rates in 3 state medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs // Arch Gen Psychiatry. – 2010. – Vol. 67. – Pp. 17–24. – https://doi.org/10.1001/archgenpsychiatry.2009.179
  39. Mangurian C., Giwa F., Shumway M. et al. Primary care providers’ views on metabolic monitoring of outpatients taking antipsychotic medication // Psychiatr Serv. – 2013. – Vol. 64. – Pp. 597–599. – https://doi.org/10.1176/appi.ps.002542012
  40. McLaren J.L., Brunette M.F., McHugo G.J. et al. Monitoring of patients on second-generation antipsychotics: a national survey of child psychiatrists // Psychiatr Serv. – 2017. – Vol. 68. – Art. 961. – https://doi.org/10.1176/appi.ps.201500553
  41. Клинические рекомендации. Шизофрения. Взрослые / Минздрав РФ. – Москва, 2024. – 217 с.
  42. Kornetova E.G., Kornetov A.N., Mednova I.A. et al. Changes in body fat and related biochemical parameters associated with atypical antipsychotic drug treatment in schizophrenia patients with or without metabolic syndrome // Front Psychiatry. – 2019. – Vol. 10. – Art. 803. – https://doi.org/10.3389/fpsyt.2019.00803
  43. Abdulhaq B., Dardas L.A., Sami O. Monitoring for the metabolic side effects of second–generation antipsychotic medications: Psychiatrists’ views and practices // Perspect Psychiatr Care. – 2021. – Vol. 57. – Pp. 1237–1243. – https://doi.org/10.1111/ppc.12679
  44. Ijaz S., Bolea B., Davies S. et al. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: A review of systematic reviews // BMC Psychiatry. – 2018. – Vol. 18. – Art. 275. – https://doi.org/10.1186/s12888-018-1848-y
  45. Горобец Л.Н., Буланов В.С., Литвинов А.В. Эффективность и переносимость коррекционной терапии частичным агонистом дофаминовых рецепторов арипипразолом нейролептической гиперпролактинемии у больных с расстройствами шизофренического спектра // Социальная и клиническая психиатрия. – 2023. – № 2. – С. 42–50.
  46. Siwek M., Wojtasik–Bakalarz K., Krupa A.J., Chrobak A.A. Brexpiprazole-pharmacologic properties and use in schizophrenia and mood disorders // Brain Sci. – 2023. – Vol. 13. – Art. 397. – https://doi.org/10.3390/brainsci13030397
  47. Медведев В.Э. Комплексная терапия шизофрении: проблемы и решения // Психиатрия и психофармакотерапия. – 2023. – № 5. – С. 29–42.
  48. Быков Ю.В., Беккер Р.А. Антипсихотик третьего поколения арипипразол: эффективность и безопасность при расстройствах шизофренического спектра (анализ современных данных) // Психиатрия и психофармакотерапия. – 2023. – № 2. – С. 17–34.

Downloads

Download data is not yet available.